Blocking of programmed cell death-ligand 1 (PD-L1) expressed on endothelial cells promoted the recruitment of CD8+IFN-γ+ T cells in atherosclerosis

Li, Qi; Wei, Simeng; Li, Yue; Wu, Fengjiao; Qin, Xiaoxia; Li, Zhongsha; Li, Jingyu; Chen, Chang

doi:10.1007/s00011-023-01703-5

Cited by 4 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibodies that block PD‐L1 and PD‐L2 on ECs showed a synergistic effect with PHA in the activation of CD8 + T cells 146 . Similarly, blocking PD‐L1 on mouse ECs enhanced the activity of CD8 + cytotoxicity T cells 147 . Physiologically, the presence of PD‐L1 or PD‐L2 on ECs allows the extravasation of T cells without damaging the blood vessels excessively 44 .…”

Section: Mechanism Of Synergistic Effect Between Anti‐angiogenic Agen...mentioning

confidence: 95%

“…146 Similarly, blocking PD-L1 on mouse ECs enhanced the activity of CD8 þ cytotoxicity T cells. 147 Physiologically, the presence of PD-L1 or PD-L2 on ECs allows the extravasation of T cells without damaging the blood vessels excessively. 44 In various malignancies, PD-L1 is expressed on ECs and correlated with the decreased number and energetic phenotype of tumor-infiltrated T cells.…”

Section: Antigen Presentation By Ecsmentioning

confidence: 99%

See 1 more Smart Citation

Anti‐angiogenic therapy enhances cancer immunotherapy: Mechanism and clinical application

Li,

Fang

2024

Interdisciplinary Medicine

View full text Add to dashboard Cite

Immunotherapy, specifically immune checkpoint inhibitors, is revolutionizing cancer treatment, achieving durable control of previously incurable or advanced tumors. However, only a certain group of patients exhibit effective responses to immunotherapy. Anti‐angiogenic therapy aims to block blood vessel growth in tumors by depriving them of essential nutrients and effectively impeding their growth. Emerging evidence shows that tumor vessels exhibit structural and functional abnormalities, resulting in an immunosuppressive microenvironment and poor response to immunotherapy. Both preclinical and clinical studies have used anti‐angiogenic agents to enhance the effectiveness of immunotherapy against cancer. In this review, we concentrate on the synergistic effect of anti‐angiogenic and immune therapies in cancer management, dissect the direct effects and underlying mechanisms of tumor vessels on recruiting and activating immune cells, and discuss the potential of anti‐angiogenic agents to improve the effectiveness of immunotherapy. Lastly, we outline challenges and opportunities for the anti‐angiogenic strategy to enhance immunotherapy. Considering the increasing approval of the combination of anti‐angiogenic and immune therapies in treating cancers, this comprehensive review would be timely and important.

show abstract

Section: Mechanism Of Synergistic Effect Between Anti‐angiogenic Agen...mentioning

confidence: 95%

Section: Antigen Presentation By Ecsmentioning

confidence: 99%

Anti‐angiogenic therapy enhances cancer immunotherapy: Mechanism and clinical application

Li,

Fang

2024

Interdisciplinary Medicine

View full text Add to dashboard Cite

show abstract

“…The presence of TME appears to promote the expression of PD-L1 in ECs, with VEGFA and hypoxia playing a pivotal role in this process [ 85 ]. Previous research suggests that the regulation of PD-L1 in ECs may be crucial for modulating immune responses [ 160 ]. Anlotinib in particular, suppresses PD-L1 expression in TECs and retards tumor cell proliferation [ 85 ].…”

Section: Ecs-related Immune Checkpoints In the Tme: Implications And ...mentioning

confidence: 99%

Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications

Fang,

Lu,

Zheng

et al. 2023

Cell Death Dis

View full text Add to dashboard Cite

The tumor microenvironment (TME) is a highly intricate milieu, comprising a multitude of components, including immune cells and stromal cells, that exert a profound influence on tumor initiation and progression. Within the TME, angiogenesis is predominantly orchestrated by endothelial cells (ECs), which foster the proliferation and metastasis of malignant cells. The interplay between tumor and immune cells with ECs is complex and can either bolster or hinder the immune system. Thus, a comprehensive understanding of the intricate crosstalk between ECs and immune cells is essential to advance the development of immunotherapeutic interventions. Despite recent progress, the underlying molecular mechanisms that govern the interplay between ECs and immune cells remain elusive. Nevertheless, the immunomodulatory function of ECs has emerged as a pivotal determinant of the immune response. In light of this, the study of the relationship between ECs and immune checkpoints has garnered considerable attention in the field of immunotherapy. By targeting specific molecular pathways and signaling molecules associated with ECs in the TME, novel immunotherapeutic strategies may be devised to enhance the efficacy of current treatments. In this vein, we sought to elucidate the relationship between ECs, immune cells, and immune checkpoints in the TME, with the ultimate goal of identifying novel therapeutic targets and charting new avenues for immunotherapy.

show abstract

“…CD8 + Tc17 T cells do not affect the development of early AS although they accumulate in the lesioned areas of mice with AS ( van Duijn et al, 2021 ). In contrast, CD8 + IFN-γ + T cells mediate the upregulation of immune responses and secretion of pro-inflammatory cytokines during the progressive phase of AS, exacerbating AS load and promoting the inflammatory response ( Li et al, 2023 ). On the one hand, inflammatory cytokines produced by CD8 + T cells exacerbate the inflammatory response and drive the progression and instability of atherosclerotic lesions.…”

Section: Role Of Immune Cells In Asmentioning

confidence: 99%

Targeting gut microbiota and immune crosstalk: potential mechanisms of natural products in the treatment of atherosclerosis

Jing,

Guo,

Dai

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Atherosclerosis (AS) is a chronic inflammatory reaction that primarily affects large and medium-sized arteries. It is a major cause of cardiovascular disease and peripheral arterial occlusive disease. The pathogenesis of AS involves specific structural and functional alterations in various populations of vascular cells at different stages of the disease. The immune response is involved throughout the entire developmental stage of AS, and targeting immune cells presents a promising avenue for its treatment. Over the past 2 decades, studies have shown that gut microbiota (GM) and its metabolites, such as trimethylamine-N-oxide, have a significant impact on the progression of AS. Interestingly, it has also been reported that there are complex mechanisms of action between GM and their metabolites, immune responses, and natural products that can have an impact on AS. GM and its metabolites regulate the functional expression of immune cells and have potential impacts on AS. Natural products have a wide range of health properties, and researchers are increasingly focusing on their role in AS. Now, there is compelling evidence that natural products provide an alternative approach to improving immune function in the AS microenvironment by modulating the GM. Natural product metabolites such as resveratrol, berberine, curcumin, and quercetin may improve the intestinal microenvironment by modulating the relative abundance of GM, which in turn influences the accumulation of GM metabolites. Natural products can delay the progression of AS by regulating the metabolism of GM, inhibiting the migration of monocytes and macrophages, promoting the polarization of the M2 phenotype of macrophages, down-regulating the level of inflammatory factors, regulating the balance of Treg/Th17, and inhibiting the formation of foam cells. Based on the above, we describe recent advances in the use of natural products that target GM and immune cells crosstalk to treat AS, which may bring some insights to guide the treatment of AS.

show abstract

Blocking of programmed cell death-ligand 1 (PD-L1) expressed on endothelial cells promoted the recruitment of CD8+IFN-γ+ T cells in atherosclerosis

Cited by 4 publications

References 32 publications

Anti‐angiogenic therapy enhances cancer immunotherapy: Mechanism and clinical application

Anti‐angiogenic therapy enhances cancer immunotherapy: Mechanism and clinical application

Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications

Targeting gut microbiota and immune crosstalk: potential mechanisms of natural products in the treatment of atherosclerosis

Contact Info

Product

Resources

About